Search results
Results from the WOW.Com Content Network
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
The most effective malaria vaccine is the R21/Matrix-M, with a 77% efficacy rate shown in initial trials and significantly higher antibody levels than with the RTS,S vaccine. It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy, [6] [7] and only the second malaria vaccine ...
This vaccine is the first to meet the World Health Organization's Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy. [145] Germany-based BioNTECH SE is developing an mRNA-based malaria vaccine BN165 [146] which has recently initiated a Phase 1 study [clinicaltrials.gov identifier: NCT05581641] in December 2022. The ...
The WHO-prequalified vaccine, called TAK-003, is recommended for children 6–16 years old who are in environments where dengue spread is high and burdensome on public health.
A new vaccine candidate was more than 83 percent effective at protecting against hospitalizations over a three-year clinical trial. Dengue virus is a mosquito-borne disease that can cause severe ...
In May 2024, TAK-003 became the second dengue vaccine to be prequalified by the World Health Organization (WHO). [51] This live-attenuated vaccine, developed by Takeda is similar to the Dengvaxia vaccine in the fact that it contains a weakened version of the four variants of dengue virus. The difference between the two vaccines is the TAK-003 ...
RTS,S/AS01 (commercial name Mosquirix) is the only malaria vaccine approved and in current use. The vaccine's use requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. [3] The vaccine reduces hospital admissions from severe malaria by around 30%. [3]
For example, the human body louse transmits the bacterium Rickettsia prowazekii which causes epidemic typhus. Although invertebrate-transmitted diseases pose a particular threat on the continents of Africa, Asia and South America, there is one way of controlling invertebrate-borne diseases, which is by controlling the invertebrate vector.